Skip to main content

Advertisement

SpringerLink
Log in

Two-year changes of bone mineral density in steroid-treated myasthenia gravis

  • Letter to the Editor
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Matsumoto T, Yamamoto K, Takeuchi T, Tanaka Y, Tanaka S, Nakano T, Ito M, Tomomitsu T, Hirakawa A, Soen S (2020) Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA). J Bone Miner Metab 38:522–532

    Article  CAS  Google Scholar 

  2. Konno S, Suzuki S, Masuda M, Nagane Y, Tsuda E, Murai H, Imai T, Fujioka T, Suzuki N, Utsugisawa K (2015) Association between glucocorticoid-induced osteoporosis and myasthenia gravis: a cross-sectional study. PLoS ONE 10:e0126579

    Article  Google Scholar 

  3. Yeh JH, Chen HJ, Chen YK, Chiu HC, Kao CH (2014) Increased risk of osteoporosis in patients with myasthenia gravis: a population-based cohort study. Neurology 83:1075–1079

    Article  Google Scholar 

  4. Lv F, Guan Y, Ma D, Xu X, Song Y, Li L, Jiang Y, Wang O, Xia W, Xing X, Li M (2018) Effects of alendronate and alfacalcidol on bone in patients with myasthenia gravis initiating glucocorticoids treatment. Clin Endocrinol 88:380–387

    Article  CAS  Google Scholar 

  5. Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R, Chapurlat R, Wang A, Pannacciulli N, Lerns WF (2018) Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol 6:445–454

    Article  CAS  Google Scholar 

Download references

Funding

This work was supported by JSPS KAKENHI Grant Number JP20H03592.

Author information

Authors and Affiliations

  1. Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan

    Shigeaki Suzuki

Authors
  1. Shigeaki Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SS had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Corresponding author

Correspondence to Shigeaki Suzuki.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Suzuki, S. Two-year changes of bone mineral density in steroid-treated myasthenia gravis. J Bone Miner Metab 39, 723–724 (2021). https://doi.org/10.1007/s00774-020-01181-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-020-01181-3

Search

Navigation